Biohaven's pipeline is broad with multiple late stage molecules. Analysis based on Biohaven's 01/2025 J.P. Morgan Healthcare Conference Highlights and Presentation, Q3 2024 Earnings Release, and ...

Before market open, Biohaven announced that the U.S. Food and Drug Administration (FDA) had accepted its New Drug Application (NDA) for troriluzole. This is a once-daily oral treatment for adults ...

Biohaven (BHVN) announced that the FDA has accepted for review the company’s New Drug Application, or NDA, for troriluzole for the treatment of adult patients with spinocerebellar ataxia, or SCA ...

Troriluzole has a well-established safety profile and if approved, would be the first and only FDA-approved treatment for SCA; subject to receipt of FDA approval, Biohaven is prepared to ...

Approval could come rather soon. Before market open, Biohaven announced that the U.S. Food and Drug Administration (FDA) had accepted its New Drug Application (NDA) for troriluzole. This is a once ...

Deutsche Bank initiated coverage of Biohaven (BHVN) with a Buy rating and $65 price target Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks ...

In trading on Tuesday, shares of Biohaven Ltd (Symbol: BHVN) crossed above their 200 day moving average of $40.76, changing hands as high as $42.68 per share. Biohaven Ltd shares are currently ...

(MENAFN- PR Newswire) Melissa Beiner, M.D., SCA Clinical Development Lead at Biohaven, commented, "Our NDA filing is the culmination of over 8 years of clinical research and represents an ...

Check Out Our Latest Analysis on BHVN Biohaven Stock Performance Shares of NYSE:BHVN opened at $38.40 on Monday. Biohaven Ltd. has a 52 week low of $26.80 and a 52 week high of $62.21. The firm ...